Organization & Developments: eFFECTOR Therapeutics

Parents

2021: eFFECTOR: Developing New Class Of Cancer Therapies
2023: eFFECTOR Receives U.S. FDA Fast Track Designation for Zotatifin in Combination with Fulvestrant and Abemaciclib for Treatment of ER+/HER2- Advanced Metastatic Breast Cancer
2024: The end of eFFECTOR Therapeutics: Oncology biotech winds down after mid-stage fail
eFFECTOR is developing translation regulators to selectively block disregulated translation impacting tumor growth and survival.
The company has selected control of mRNA translation as a key point of theerapeutic intervention, providing potency and selectivity while inhibiting growth of cancer cells.